Objective: The objective of this paper is to develop novel classification criteria to distinguish between unclear systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD) cases. Methods: A total of 205 variables from 111 SLE and 55 MCTD patients were evaluated to uncover unique molecular and clinical markers for each disease. Binomial logistic regressions (BLRs) were performed on currently used SLE and MCTD classification criteria sets to obtain six reduced models with power to discriminate between unclear SLE and MCTD patients that were confirmed by receiving operating characteristic (ROC) curve. Decision trees were employed to delineate novel classification rules to discriminate between unclear SLE and MCTD patients. Results: SLE and MCTD patients exhibited contrasting molecular markers and clinical manifestations. Furthermore, reduced models highlighted SLE patients exhibiting prevalence of skin rashes and renal disease while MCTD cases show dominance of myositis and muscle weakness. Additionally decision tree analyses revealed a novel classification rule tailored to differentiate unclear SLE and MCTD patients (Lu-vs-M) with an overall accuracy of 88%. Conclusions: Validation of our novel proposed classification rule (Lu-vs-M) includes novel contrasting characteristics (calcinosis, CPK elevated and anti-IgM reactivity for U1-70K, U1A and U1C) between SLE and MCTD patients and showed a 33% improvement in distinguishing these disorders when compared to currently used classification criteria sets. Pending additional validation, our novel classification rule is a promising method to distinguish between patients with unclear SLE and MCTD diagnosis. Lupus (2017) 26, 150-162.
Introduction
Mixed connective tissue disease (MCTD), also known as Sharp's syndrome, was first described in 1972 as an autoimmune disease characterized by high titers of antibodies to U1 small nuclear ribonucleoprotein particle (snRNP) and additional features that overlapped with multiple rheumatic diseases including lupus. 1 There are a number of serological and clinical characteristics that support the independent nature of MCTD versus lupus. 2 For example, MCTD patients typically express elevated autoantibodies targeting U1 snRNP-specific proteins known as U1-70K, U1A and U1C while those with SLE show anti-Smith (Sm) and antidouble-stranded DNA (anti-dsDNA) antibodies. 3 Though some SLE patients develop an anti-U1 snRNP response, they are able to retain immunoglobulin (Ig)M reactivity against these antigens while those with MCTD switch to an IgG response. [4] [5] [6] Likewise, severe renal and central nervous system (CNS) manifestations are observed in SLE patients 7 while lung and heart pathologies are frequent in MCTD patients. 8, 9 Given the contrasting clinical characteristics and differing organ involvements reported in SLE and MCTD patients, the recognition of MCTD has become imperative in clinical practice. 10, 11 However, the two major classification criteria sets for SLE and four classification rules for MCTD were designed to recognize either of these diseases but not to differentiate between them. [12] [13] [14] As mentioned later, a number of currently used laboratory tests lack the power to accurately distinguish MCTD from SLE. The aim of this study is to develop novel classification criteria specifically designed to distinguish between unclear SLE and MCTD patients. To achieve this, 205 clinical and laboratory test variables were evaluated in the patient cohort (111 SLE and 55 MCTD). Using decision tree (DT) analyses, a novel, custom-made rule was created to classify unclear SLE and MCTD patients with an overall accuracy of 88% representing a 33% improvement from currently used classification criteria sets. Additionally, we identified two panels of blood biomarkers that correlate with specific organ involvement in either SLE or MCTD patients. In summary, this report, for the first time, proposes a novel classification rule for the distinction of SLE and MCTD, especially for patients exhibiting unclear clinical characteristics and overlapping or nonspecific molecular marker results.
Patients and methods

Selection and diagnosing of SLE and MCTD patients
In this study SLE (111) or MCTD (55) diagnoses of 166 patients were determined prior to initiation of this project by two expert clinical rheumatologists versed in lupus and MCTD, Drs Robert W. Hoffman and Eric L. Greidinger. Both clinicians agreed on the diagnosis with their independent evaluations in all but five cases. In these cases, the clinicians met together, discussed the cases, and agreed on the most appropriate diagnosis. Their reported consensus diagnoses were recorded following the Florida International University and University of Miami Institutional Review Board (IRB)-accepted protocols (IRB numbers: 040308-00 as well as 20030724 and 20040286, respectively) and used as the gold standard for diagnosis in this investigation. Subsequently, two clinically validated lupus criteria sets known as the 1997 American College of Rheumatology (ACR) criteria and the 2012 Systemic Lupus International Collaborative Clinics (SLICC) criteria were applied to each of the 166 patients to determine the SLE diagnoses according to these lupus criteria sets. 13, 14 Similarly, the four currently used rules for the classification of MCTD (Alarco´n-Segovia, Sharp, Kasukawa and Kahn criteria) were also used for each of the 166 patients to access the MCTD classification based on the MCTD rule. 12, 13 Based on these classification schemes, we further subdivide SLE and MCTD cohorts into clear and unclear subgroups. Clear (classical) SLE patients were defined as those fulfilling both SLE classification criteria sets (ACR and SLICC) but none of the four MCTD classification criteria sets (Alarco´n-Segovia, Sharp, Kasukawa and Kahn criteria) (n ¼ 33 SLE). ''Unclear'' (non-classical) patients are those who did not meet all of the criteria sets for either SLE or MCTD and/or simultaneously fulfilled at least one classification criteria set for both SLE and at least one MCTD (n ¼ 133, SLE ¼ 78 and MCTD ¼ 55). All 55 MCTD patients evaluated in this study were defined as unclear cases given that none of them fulfilled all four MCTD classification criteria sets and/or fulfilled at least one SLE classification criteria set. All the individuals included represent well-characterized patients who have been the subjects of previous publications. 5, 6, [15] [16] [17] 
Collection of clinical data
A total of 205 variables were obtained for the 166 study patients (Supplementary file 1). These variables included 74 clinical symptoms, 76 traditional laboratory tests and 55 experimental blood markers. All the clinical variables were recorded on the same date that the blood and/or urine samples were collected from the patients. The traditional laboratory tests refer to standardized commercial laboratory assays performed during the clinical care of patients with SLE or MCTD. Experimental blood markers variables include 18 cytokines and IgM reactivity for 15 different peptides derived from U1 snRNP. Experimental cytokines were evaluated to determine the potential difference between SLE and MCTD cohorts. Likewise, IgM reactivity for the U1 snRNP subunit was considered in the analyses since contrasting responses in SLE and MCTD patients have been reported. 6 A detailed description of each of the clinical manifestations as well as normal range and cutoff values for traditional and experimental laboratory tests are listed in Supplementary file 1.
Construction of reduced classification criteria models to identify between unclear SLE and MCTD patients
The variables composing each of the two classification criteria sets for SLE (ACR and SLICC) and four classification criteria sets for MCTD Can SLE classification rules be effectively applied to diagnose unclear SLE cases? A Mesa et al.
(Alarco´n-Segovia, Sharp, Kasukawa and Kahn) were employed in six independent forward binomial logistic regression (BLR) analyses performed with unclear SLE (n ¼ 78) and MCTD (n ¼ 55) patients in SPSS (version 18). These analyses revealed which variables combinations improved the distinction between unclear SLE and MCTD when compared to each of the individual variables evaluated (p 0.05). Six reduced models were obtained corresponding to smaller versions of each of the existing six classification criteria sets. The accuracy, sensitivity and specificity for each of the reduced models to classify unclear SLE and MCTD patients were calculated. Receiving operating characteristics (ROC) curves ranked their power to differentiate between unclear SLE and MCTD patients.
Identifying variables to develop a new classification rule for SLE and MCTD discrimination
Since this study includes 205 clinical variables but only 166 patients, an initial selection of variables was required to maintain stability and robustness of any subsequent statistical analysis performed. The objective was to develop a new classification rule customized for discriminating unclear SLE and MCTD patients, therefore all the variables showing significant difference between patients with these autoimmune disorders were selected (p 0.05). Likewise, all features included in each of the reduced classification criteria models were also chosen given that forward BLR demonstrated their improved power to discriminate between unclear SLE and MCTD patients (p 0.05). The resulting variables selected to build a new classification rule included 68 clinical manifestations, 28 traditional laboratory tests and five experimental blood markers (Supplementary file 2). Valvular heart disease; laboratory blood tests for calcium, albumin/globulin, and creatine kinase; as well as the interleukin 17A (IL-17A) experimental assay were initially selected but could not be included in the subsequent statistical analysis given the reduced number of patients with available values for these variables.
Developing novel classification models for differentiation between unclear SLE and MCTD patients
Novel SLE/MCTD discrimination models were created by using DTs in R (rpart version 4.1-8) using the reduced dataset as above (Supplementary file 2). First, unclear SLE and MCTD patients were randomly subdivided into three independent subgroups: training set (unclear SLE ¼ 47 and MCTD ¼ 33), test set (unclear SLE ¼ 15 and MCTD ¼ 11) and validation set (unclear SLE ¼ 16 and MCTD ¼ 11). The training set was used to construct DTs in which the participants were sampled with replacement until a set of 1000 observations was collected. Using the rpart package for R (version 4.1-8), recursive partitioning was performed on these observations to create a classification tree for unclear SLE and MCTD. A plot of the tree was generated using the ggplot2 package (version 0.9.3.1). Each variable in the tree represents a decision. If the value for the variable in a patient is true (i.e. the symptom is observed), follow the branch of the tree to the right. If not observed, follow the branch to the left. Repeat for each variable encountered until a conclusion, ''SLE'' or ''MCTD,'' is reached. In this way, a total of three independent DTs were created using the training set that were subsequently applied to the test set (Supplemental file 3). The accuracy, specificity and sensitivity of each of the trees per sample set analyzed were calculated using confusion matrix and recorded in Supplemental file 3. The tree for whose performance on the training set and test set were as close to each other as possible was selected as the best novel rule in classifying unclear SLE and MCTD patients and abbreviated as ''Luvs-M.'' The proposed novel classification rule was applied to the validation set, and the accuracy, sensitivity and specificity were recorded and compared with currently used classification rules using samples from the same validation set.
Statistical analyses
Missing data analyses were performed in SPSS (version 18) to confirm that differences observed between SLE and MCTD populations were authentic and not driven by missing values through the entire database. Significant differences between SLE and MCTD patients for each of the 200 clinical variables included in this study were determined by Chi ()-squared or independent sample T test in SPSS (version 18) when the value was nominal or numerical, respectively (p 0.05). Bull's eye plots were created in R (version 4.1-8) to represent variables with significantly different frequencies between the two disease states. Correlations between laboratory tests and clinical manifestations observed in either SLE or MCTD patients were determined by T-test/analysis of variance (ANOVA) with repeated measurements to ensure robustness (p 0.05). The resulting p values for each of the correlations were used to construct a heat map for each autoimmune 
Results
Evaluating classification power of existing classification criteria sets
Each of the six criteria sets for either SLE or MCTD classification was applied to the patient cohort to evaluate its capacity to distinguish between these autoimmune syndromes ( Table 1) . As expected, SLE classification criteria sets are the best in identifying clear SLE patients while MCTD classification rules are the best at detecting clear MCTD cases. Nevertheless, comparison among these rules highlights the limitations of these criteria sets in discerning between SLE and MCTD patients. The Alarco´n-Segovia criteria showed the highest capacity to differentiate SLE and MCTD cases with 72.39% accuracy. The rest of the five classification criteria sets revealed a similar mean capacity to distinguish between these two diseases ranging from 60.76% (Kasukawa) to 69.40% (Kahn) accuracy.
Contrasting clinical and serological features exhibited by SLE and MCTD patients
Each of the 205 clinical variables included in this study (Supplementary file 1) was individually evaluated to assess significant differences between SLE and MCTD populations. We identified 35 variables that significantly differ between these autoimmune diseases including clinical symptoms related to skin, muscle, kidney and heart tissues as well as18 serological assays (p 0.05) ( Figure 1 ). Molecular marker associations with unique tissue damage are specific to either SLE or MCTD patients
Each of the laboratory tests analyzed in this study was individually correlated with clinical symptoms presenting in patients diagnosed with SLE ( Figure 2 ) or MCTD ( Figure 3 ). The markers with significant correlation to either SLE or MCTD (but not both) are listed in Table 2 . The resulting p value heat map uncovered that individual clinical manifestations in the SLE cohort were significantly associated with particular lab abnormalities. Elevated IL33 was associated with oral ulcers, leukopenia and lymphopenia; high IL12p40 was associated with telangiectasia and joint deformity; and increased B-cell-activating factor (BAFF) was associated with thrombosis (p 0.05) ( Table 2 and Figure 2 ). Different correlations were detected in the MCTD cohort, for whom molecular markers were significantly associated with nasal ulcers (high BAFF), oral ulcers (elevated IL33), anemia (low C3 and C4 levels, as well as high IgM and IgG rheumatoid factor titer) and pleuritis (increased IL17A) (p 0.05) ( Table 2 and Figure 3 ). It is noteworthy that IL33 correlates with oral ulcers equally in SLE and MCTD (p 0.05). Interestingly, 44% (4/9) of the lab tests that show significant correlations with specific clinical symptoms corresponded to experimental serologic assays ( Table 2) .
Regression analysis of existing classification criteria sets uncover essential factors required for classification of unclear SLE and MCTD patients
Six independent forward BLR analyses with variables corresponding to those listed in each of the six existing classification criteria were performed to construct six reduced models for unclear SLE (n ¼ 78) and MCTD (n ¼ 45) patients. Evaluation of the reduced models exposed six combinations from 18 essential features with significant power to differentiate between unclear SLE and MCTD cases ( Table 3 ). Comparison among the six reduced models revealed that the reduced Kasukawa (rKasukawa) showed the highest accuracy (88%) at differentiating between these autoimmune syndromes derived from the combination of Raynaud's phenomenon, malar rash, adenopathies, sclerodactyly and muscle weakness (p 0.05) ( Table 3) . Except for malar rash (which higher frequency in unclear SLE than MCTD cases), Raynaud's phenomenon, adenopathies, sclerodactyly and muscle weakness were more frequent in MCTD patients when compared to unclear SLE patients (p 0.05) ( Table 3 ). The rKasukawa was also a better classifier than the Alarco´n-Segovia classification criteria to discriminate between unclear SLE and MCTD patients (p 0.05) ( Tables 1 and 3) . Indeed, all the reduced models were better classifiers for unclear SLE and MCTD patients when compared to their corresponding complete class criteria (Tables 1 and 3) .
ROC curves confirmed the classification power of reduced class criteria models
A total of six individual ROC curves analyses were performed to confirm the segregation power of the variable per criteria set when compared to the corresponding complete classification criteria (Table 1) as well as the newly proposed reduced models ( Table 3 ). As expected, the ROC analysis confirmed that most of the reduced models were better Can SLE classification rules be effectively applied to diagnose unclear SLE cases? A Mesa et al.
classifiers for patients with unclear autoimmune syndromes than any of the existing complete class criteria or any individual variable included in them (p 0.0001) ( Figure 4 ). Based on ROC analyses, the reduced Alarco´n-Segovia model failed to increase differentiation between unclear SLE and MCTD patients when compared to the complete class criteria (p 0.0001) ( Figure 5 ). Furthermore, the analyses revealed that two laboratory tests previously identified by BLR (positive dsDNA and RNP in Table 3 ) have individual power to distinguish between unclear SLE and MCTD cases (p 0.05) (Figure 4) . Also, eight of the clinical symptoms predicted by BLR (synovitis, malar rash, acrosclerosis, Raynaud's, esophageal hypomotility, sclerodactyly and muscle weakness in Table 3 ) have individual power to segregate between unclear SLE and MCTD (p 0.05) ( Figure 4 ). Hand swelling, proximal scleroderma, any clot, valvular heart diseases, pulmonary hypertension, pulmonary fibrosis, gastric reflux, lymph nodes swelling, morning stiffness, myocardial infarction and interleukin receptor BAFFR were initially considered in the analysis but not included due to the reduced sample size for each of these variables.
Construction of a novel classification rule to assist diagnosing of unclear SLE and MCTD cases
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Validation and comparison of a novel classification rule for unclear SLE and MCTD patients
The proposed classification rule (Lu-vs-M) was applied to the validation subset that contains unclear SLE (n ¼ 16) and MCTD (n ¼ 11) patients who were not included in the training or test sets used to construct and examine, respectively, our novel proposed Lu-vs-M rule. This validation step revealed that the novel Lu-vs-M rule had an accuracy, sensitivity and specificity of 96%, 62% and 50%, respectively ( Table 4 ). All six currently used classification rules were also applied to the samples in the validation subset to establish a direct comparison in the performance of each of the criteria sets. Accuracy of currently used criteria sets to distinguish unclear SLE and MCTD cases ranges from 63% (SLICC) to 22% (Alarco´n-Segovia) ( Table 4) . Therefore, our novel Lu-vs-M rule represents the best evaluated criteria set to differentiate unclear SLE and MCTD patients and provides a 33% improvement in accuracy from currently used disease classification criteria sets.
Discussion
Since its initial description by Sharp et al., 1 the recognition of MCTD as a unique disease has been challenged, often because of overlapping characteristics shared by patients diagnosed with SLE. 18, 19 Nevertheless, the reported contrasting organ involvement in patients with diagnosis of MCTD (lung and heart) when compared to those with SLE (kidney and CNS) provides evidence of the clinical relevance of the MCTD concept to prevent and/or treat organ malfunction in these autoimmune syndromes, regardless of whether MCTD is recognized as a separate illness or is judged to be merely a subtype of SLE. Available and currently used classification criteria sets were developed to identify either SLE (ACR and SLICC) or MCTD (Alarco´n-Segovia, Sharp, Kasukawa and Kahn) patients but have not been optimized to distinguish between these autoimmune diseases. Analyses of all criteria sets available for the classification of either SLE or MCTD revealed that these six established 13, 14 In our cohort, most of the SLE and MCTD patients did not represent clear (or classical) cases that follow all the variables (or most) in each of the criteria sets ( Figure 6 ). Rather, ''unclear'' cases exhibiting a variety of clinical symptoms and laboratory tests described by SLE as well as MCTD classification criteria sets led to difficulties in disease classification ( Figure 6 ). In fact, only 20% of patients (n ¼ 33 SLE cases) evaluated in this cohort represented clear SLE cases while 80% were unclear cases (SLE ¼ 78 and MCTD ¼ 55). As previously reported, 3,20,21 elevated levels of anti-dsDNA, anti-Sm, red blood cell casts, thrombocytopenia, non-erosive arthritis as well as pleuritic and/or pericarditis are present in clear SLE cases. By contrast, unclear patients exhibit elevated frequencies of synovitis and tenderness in two or more joints, pericarditis and leukopenia (p 0.01) as has been previously reported. 22 The proposed reduced models from currently used classification criteria sets highlight clinical and molecular Figure 4 Specific blood markers correlate with clinical symptoms in MCTD patients. Laboratory tests performed in MCTD subjects are displayed on the ''y'' axis while clinical manifestations exhibit in this patient population are on the ''x'' axis. The white, blue and red boxes indicate significant correlations, significant correlations after Bonferroni corrections and no correlations, respectively (p 0.05). Proteinuria, hematuria and cellular casts; stroke; venous clot; lung disease; synovitis; symmetric swelling of the joints; observed proximal muscle weakness and calcinosis were initially considered for the correlations but not included in the final analyses given the reduced sample size available in the MCTD cohort for these variables.
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features that help unclear SLE and MCTD differentiation (Table 3 ).
In congruency with previous reports, [3] [4] [5] [6] [7] [8] [9] our statistical analysis of 205 variables documented for SLE and MCTD patients revealed 35 clinical manifestations and 18 molecular features significantly different between the two conditions ( Figure 1) . The high prevalence of skin rashes and renal disease in SLE and high incidence of myositis and muscle weakness in MCTD patients that emerged from our statistical analysis were reassuringly consistent with typical clinical manifestations associated with each of these autoimmune conditions. 7-9,23-25
The regression analyses identified six reduced versions of the existing classification criteria sets with improved capacity to distinguish between unclear SLE and MCTD cases (p 0.05) ( Table 3 ) ( Figure 4) . Particularly, the rKasukawa, which includes Raynaud's, adenopathies, malar rash, sclerodactyly and muscle weakness, exhibited the highest discrimination power between unclear SLE and MCTD with 88% accuracy. The segregation power of the rKasukawa model was not surprising given that the clinical characteristics within it have been reported to be contrasting in SLE and MCTD patients. 3, 4 In this way, our presented approach not only showed power to distinguish between SLE and MCTD cases but potentially could be used to differentiate other disorders that are difficult to classify and therefore diagnose.
Our novel Lu-vs-M rule for differentiating unclear SLE and MCTD patients exhibited 33% higher accuracy than currently used classification methods (Table 4 ) and is composed of 16 variables including seven laboratory tests and nine clinical symptoms and syndromes ( Figure 5 ). Calcinosis, elevated CPK and anti-IgM reactivity for U1-70K, U1A and U1C represent novel characteristics included in this new Lu-vs-M rule but not in any of the other six currently available classification sets. Of note, 69% of the factors listed in our novel rule are part of existing SLE or MCTD classification criteria sets. Furthermore, with the exception of photosensitivity, lung disease and three laboratory tests (anti-DNA, anti-Sm and low C3), the absence rather than the presence of the rest of the characteristics is prevalent in the SLE but not MCTD cases. This could explain how unclear SLE and MCTD patients could be overlooked since they appear to lack the expression of symptoms associated with each of these diseases. The fact that our new proposed Lu-vs-M rule maintained discrimination power when applied to a validation subset of SLE and MCTD patients (96% accuracy, 62% sensitivity and 50% specificity) provides evidence of the potential clinical utility of this novel Lu-vs-M criteria set when dealing with unclear SLE and MCTD cases. Can SLE classification rules be effectively applied to diagnose unclear SLE cases? A Mesa et al.
